Trial Profile
To Evaluate Efficacy and Safety of Daclatasvir with Sofosbuvir or Simeprevir in Liver Transplant (Lt) Recipients with Severe Recurrent Hepatitis C virus Genotype 1 Infection
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Feb 2016
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Simeprevir; Sofosbuvir
- Indications Hepatitis C
- Focus Therapeutic Use
- 17 Feb 2016 Results published in the Liver Transplantation
- 07 Aug 2015 New trial record